These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18615074)

  • 41. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.
    Felix RS; Colleoni GW; Caballero OL; Yamamoto M; Almeida MS; Andrade VC; Chauffaille Mde L; Silva WA; Begnami MD; Soares FA; Simpson AJ; Zago MA; Vettore AL
    Cancer Lett; 2009 Jun; 278(1):41-8. PubMed ID: 19171422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.
    Masuo T; Okamura S; Zhang Y; Mori M
    Cancer Lett; 2009 Nov; 285(1):66-72. PubMed ID: 19481339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Loss of histidine decarboxylase as a marker of malignant transformation and dedifferentiation of B-cells infiltrating the skin. A case report of a therapy-resistant multiple myeloma complicated by skin infiltration.
    Varkonyi J; Karádi I; Szocs K; Sugár I; Sápi Z; Marschalko M; Pállinger E; Darvas Z; Falus A
    Acta Oncol; 2008; 47(3):458-61. PubMed ID: 17851872
    [No Abstract]   [Full Text] [Related]  

  • 44. A new MAFia in cancer.
    Eychène A; Rocques N; Pouponnot C
    Nat Rev Cancer; 2008 Sep; 8(9):683-93. PubMed ID: 19143053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Molecular pathogenesis of multiple myeloma].
    Iida S
    Rinsho Ketsueki; 2006 Mar; 47(3):196-203. PubMed ID: 16629484
    [No Abstract]   [Full Text] [Related]  

  • 46. Addicted to Myc--but why?
    von Eyss B; Eilers M
    Genes Dev; 2011 May; 25(9):895-7. PubMed ID: 21536730
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Images in pathology. Crystalline inclusions in plasma cell myeloma.
    Patriarca C; Giunta P; Di Pasquale M; Comandè M
    Int J Surg Pathol; 2007 Jul; 15(3):301. PubMed ID: 17652543
    [No Abstract]   [Full Text] [Related]  

  • 48. Transcription factor dependencies identify BAF-dependent cancers.
    McRae HM; Hargreaves DC
    Cancer Cell; 2024 Aug; 42(8):1326-1328. PubMed ID: 39029465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hierarchy of mono- and biallelic
    Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S
    Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981
    [No Abstract]   [Full Text] [Related]  

  • 50. C-Myc transrepression and cell transformation.
    Lee LA; Dang CV
    Curr Top Microbiol Immunol; 1997; 224():131-5. PubMed ID: 9308236
    [No Abstract]   [Full Text] [Related]  

  • 51. Biologic and clinical significance of cytokine production in B-cell malignancies.
    Torcia M; Aldinucci D; Carossino AM; Imreh F; Cozzolino F
    Eur J Haematol Suppl; 1989; 51():35-42. PubMed ID: 2697593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
    Ryu D; Kim HJ; Joung JG; Lee HO; Bae JS; Kim SJ; Kim H; Park WY; Kim K
    Oncotarget; 2016 Jul; 7(30):47127-47133. PubMed ID: 27223072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncogene addiction.
    Weinstein IB; Joe A
    Cancer Res; 2008 May; 68(9):3077-80; discussion 3080. PubMed ID: 18451130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer. Taking a back door to target Myc.
    Evan G
    Science; 2012 Jan; 335(6066):293-4. PubMed ID: 22267799
    [No Abstract]   [Full Text] [Related]  

  • 55. [Cellular origin of multiple myeloma].
    Qi J; Hao Y
    Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):275-7. PubMed ID: 11601218
    [No Abstract]   [Full Text] [Related]  

  • 56. MYC dysregulation in the progression of multiple myeloma.
    Misund K; Keane N; Stein CK; Asmann YW; Day G; Welsh S; Van Wier SA; Riggs DL; Ahmann G; Chesi M; Viswanatha DS; Kumar SK; Dispenzieri A; Gonzalez-Calle V; Kyle RA; O'Dwyer M; Rajkumar SV; Kortüm KM; Keats JJ; ; Fonseca R; Stewart AK; Kuehl WM; Braggio E; Bergsagel PL
    Leukemia; 2020 Jan; 34(1):322-326. PubMed ID: 31439946
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of c-myc during normal B cell proliferation, and as B cells undergo malignant transformation.
    Snow EC
    Curr Top Microbiol Immunol; 1997; 224():211-20. PubMed ID: 9308244
    [No Abstract]   [Full Text] [Related]  

  • 58. Programming plasma cell survival.
    Klein U
    J Exp Med; 2014 May; 211(5):744. PubMed ID: 24799529
    [No Abstract]   [Full Text] [Related]  

  • 59. Logic programming reveals alteration of key transcription factors in multiple myeloma.
    Miannay B; Minvielle S; Roux O; Drouin P; Avet-Loiseau H; Guérin-Charbonnel C; Gouraud W; Attal M; Facon T; Munshi NC; Moreau P; Campion L; Magrangeas F; Guziolowski C
    Sci Rep; 2017 Aug; 7(1):9257. PubMed ID: 28835615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple myeloma.
    J Tenn Med Assoc; 1978 May; 71(5):357-61. PubMed ID: 661303
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.